Rhil 5

Masitinib and midostaurin (PKC412) were purchased from LC Laboratories (Woburn, MA, USA), piceatannol and pimozide from Sigma-Aldrich (St Louis, MO, USA), RDEA119, PD0325901 and NVP-BEZ235 from Selleck (Houston, TX, USA) and RAD001 from ChemieTek (Indianapolis, IN, USA). The antibody-drug conjugate brentuximab vedotin (SGN-35) was kindly provided by Dr P. Veiby and Dr J. V. Garafalo (Millennium Takeda Oncology Company, Cambridge, MA, USA). Stock solutions of drugs were prepared by dissolving in dimethyl sulfoxide (Merck, Darmstadt, Germany). Recombinant human (rh) interleukin (IL)-2 was obtained from ImmunoTools (Friesoythe, Germany), rhIL-4 from Peprotech (Rocky Hill, NJ, USA), rhIL-5 from BD Biosciences (San Jose, CA, USA), rhIL-6 from Novartis (Basel, Switzerland), rhIL-13, rhCD30 ligand, recombinant canine (rc) IL-4, and rc stem cell factor (SCF) from R&D Systems (Minneapolis, MN, USA) and rhSCF from Strathmann Biotech (Hannover, Germany). RPMI 1640 medium and fetal calf serum (FCS) were purchased from PAA Laboratories (Pasching, Austria), ³H-thymidine from Amersham (Buckinghamshire, UK) and the Annexin V-FITC Kit from eBiosciences (San Diego, CA, USA).

Recombinant human (Rh) GM-CSF was purchased from R&D Systems Inc (Minneapolis, MN, USA), while rhIL-3 and rhIL-5 were purchased from BD Biosciences (San Jose, CA, USA). Human serum IgG was from Sigma-Aldrich (St. Louis, MO), LY294002 from Cell Signaling (Danvers, MA), and BI-D1870 and PF-4708671 from Selleckchem (Houston, TX). For the neutralization of IL-3-activated eosinophil degranulation on aggregated IgG, polyclonal goat anti-FCGRIIB/C and anti-FCGRIIA antibodies and control goat IgG were from R&D systems (Minneapolis, MN). Neutralizing anti-αM/CD11b (mouse, clone 2LPM19c) was from Biomeda (Foster City, CA), anti-ß1 integrin (rat, clone mAb13) was from Sigma, and the anti-ß7 (rat, clone Fib504) was from BD Biosciences (San Jose, CA). The control mouse IgG₁ and the control rat IgG2a were from Dako (Carpinteria, CA) and Santa Cruz Biotechnologies (Dallas, Texas), respectively. All the neutralizing anti-integrin antibodies have been described previously [33 (link)].